Short Interest in Tharimmune, Inc. (NASDAQ:THAR) Rises By 37.3%

Tharimmune, Inc. (NASDAQ:THAR) saw a large increase in short interest in the month of April. As of April 15th, there was short interest totalling 103,400 shares, an increase of 37.3% from the March 31st total of 75,300 shares. Currently, 0.9% of the shares of the company are sold short. Based on an average daily volume of 488,400 shares, the days-to-cover ratio is presently 0.2 days.

Tharimmune Stock Performance

Shares of NASDAQ:THAR traded up $0.01 on Friday, hitting $0.37. 63,108 shares of the company were exchanged, compared to its average volume of 228,185. The company’s 50 day moving average price is $0.40 and its two-hundred day moving average price is $1.43. Tharimmune has a one year low of $0.34 and a one year high of $31.50.

About Tharimmune

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).